| Thomas Matthew Wilcox, DO | |
|
4820 Riverbend Rd Ste 100, Boulder, CO 80301-2618 | |
| (303) 415-5399 | |
| (303) 297-5808 |
| Full Name | Thomas Matthew Wilcox |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 34 Years |
| Location | 4820 Riverbend Rd Ste 100, Boulder, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073629507 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | DR.0035574 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boulder Community Health | Boulder, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boulder Community Health | 6800707233 | 212 |
News Archive
Massive samples emanating from a decade-old, international initiative to determine how genetics and environment cause type 1 diabetes are giving scientists a unique perspective on which molecular and environmental factors really contribute to the disease.
Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia.
A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Therapeutic Discovery Project (QTDP) program.
CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
› Verified 4 days ago
| Entity Name | Boulder Community Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821074196 PECOS PAC ID: 6800707233 Enrollment ID: O20040123000284 |
News Archive
Massive samples emanating from a decade-old, international initiative to determine how genetics and environment cause type 1 diabetes are giving scientists a unique perspective on which molecular and environmental factors really contribute to the disease.
Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia.
A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Therapeutic Discovery Project (QTDP) program.
CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Matthew Wilcox, DO 5450 Western Ave, Boulder, CO 80301-2709 Ph: (303) 415-5399 | Thomas Matthew Wilcox, DO 4820 Riverbend Rd Ste 100, Boulder, CO 80301-2618 Ph: (303) 415-5399 |
News Archive
Massive samples emanating from a decade-old, international initiative to determine how genetics and environment cause type 1 diabetes are giving scientists a unique perspective on which molecular and environmental factors really contribute to the disease.
Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia.
A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Therapeutic Discovery Project (QTDP) program.
CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
› Verified 4 days ago
Ms. Martha E Montour, RN Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 580 Mohawk Dr, Boulder, CO 80303 Phone: 303-440-2690 | |
Chester J Dreiman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2562 Briarwood Dr, Boulder, CO 80305 Phone: 303-501-2195 | |
Pamela G Ingram, MSN Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 580 Mohawk Dr, Boulder, CO 80303 Phone: 303-554-5164 | |
Bradley D Fanestil, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4801 Riverbend Rd Ste 120b, Boulder, CO 80301 Phone: 303-415-8615 Fax: 303-293-0628 | |
Dr. Joseph Randall Lutt, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1840 Folsom St Ste 105, Boulder, CO 80302 Phone: 720-494-4706 Fax: 720-494-4706 | |
Dr. Amy O Campbell, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2880 Folsom St Ste 100, Boulder, CO 80304 Phone: 303-327-7047 Fax: 303-443-7168 | |
Wael F. Garas, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5495 Arapahoe Ave Ste 100, Boulder, CO 80303 Phone: 303-415-4250 Fax: 303-440-9629 |